PolyPeptide Group AG

Swiss Stock Exchange PPGN.SW

PolyPeptide Group AG Gross Profit Margin for the year ending December 31, 2023: 1.45%

PolyPeptide Group AG Gross Profit Margin is 1.45% for the year ending December 31, 2023, a -92.17% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

PolyPeptide Group AG Gross Profit Margin for the year ending December 31, 2022 was 18.50%, a -47.64% change year over year.
PolyPeptide Group AG Gross Profit Margin for the year ending December 31, 2021 was 35.34%, a 8.30% change year over year.
PolyPeptide Group AG Gross Profit Margin for the year ending December 31, 2020 was 32.63%, a -7.63% change year over year.
PolyPeptide Group AG Gross Profit Margin for the year ending December 31, 2019 was 35.33%, a 2.11% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Swiss Stock Exchange: PPGN.SW

PolyPeptide Group AG

CEO	Mr. Juan Jose Gonzalez
IPO Date	April 28, 2021
Location	Switzerland
Headquarters	Dammstrasse 19
Employees	1,277
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Key trends

Past 5 years